Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2008

Open Access 01-12-2008 | Research article

Vav3 oncogene activates estrogen receptor and its overexpression may be involved in human breast cancer

Authors: Kiwon Lee, Yin Liu, Jun Qin Mo, Jinsong Zhang, Zhongyun Dong, Shan Lu

Published in: BMC Cancer | Issue 1/2008

Login to get access

Abstract

Background

Our previous study revealed that Vav3 oncogene is overexpressed in human prostate cancer, activates androgen receptor, and stimulates growth in prostate cancer cells. The current study is to determine a potential role of Vav3 oncogene in human breast cancer and impact on estrogen receptor a (ERα)-mediated signaling axis.

Methods

Immunohistochemistry analysis was performed in 43 breast cancer specimens and western blot analysis was used for human breast cancer cell lines to determine the expression level of Vav3 protein. The impact of Vav3 on breast cancer cell growth was determined by siRNA knockdown of Vav3 expression. The role of Vav3 in ERα activation was examined in luciferase reporter assays. Deletion mutation analysis of Vav3 protein was performed to localize the functional domain involved in ERα activation. Finally, the interaction of Vav3 and ERα was assessed by GST pull-down analysis.

Results

We found that Vav3 was overexpressed in 81% of human breast cancer specimens, particularly in poorly differentiated lesions. Vav3 activated ERα partially via PI3K-Akt signaling and stimulated growth of breast cancer cells. Vav3 also potentiated EGF activity for cell growth and ERα activation in breast cancer cells. More interestingly, we found that Vav3 complexed with ERα. Consistent with its function for AR, the DH domain of Vav3 was essential for ERα activation.

Conclusion

Vav3 oncogene is overexpressed in human breast cancer. Vav3 complexes with ERα and enhances ERα activity. These findings suggest that Vav3 overexpression may aberrantly enhance ERα-mediated signaling axis and play a role in breast cancer development and/or progression.
Appendix
Available only for authorised users
Literature
1.
2.
Bustelo XR: Vav proteins, adaptors and cell signaling. Oncogene. 2001, 20 (44): 6372-6381. 10.1038/sj.onc.1204780.CrossRefPubMed
3.
Katzav S, Martin-Zanca D, Barbacid M: vav, a novel human oncogene derived from a locus ubiquitously expressed in hematopoietic cells. Embo J. 1989, 8 (8): 2283-2290.PubMedPubMedCentral
4.
Zugaza JL, Lopez-Lago MA, Caloca MJ, Dosil M, Movilla N, Bustelo XR: Structural determinants for the biological activity of Vav proteins. J Biol Chem. 2002, 277 (47): 45377-45392. 10.1074/jbc.M208039200.CrossRefPubMed
5.
Moores SL, Selfors LM, Fredericks J, Breit T, Fujikawa K, Alt FW, Brugge JS, Swat W: Vav family proteins couple to diverse cell surface receptors. Mol Cell Biol. 2000, 20 (17): 6364-6373. 10.1128/MCB.20.17.6364-6373.2000.CrossRefPubMedPubMedCentral
6.
Aghazadeh B, Lowry WE, Huang XY, Rosen MK: Structural basis for relief of autoinhibition of the Dbl homology domain of proto-oncogene Vav by tyrosine phosphorylation. Cell. 2000, 102 (5): 625-633. 10.1016/S0092-8674(00)00085-4.CrossRefPubMed
7.
Sommer S, Fuqua SA: Estrogen receptor and breast cancer. Semin Cancer Biol. 2001, 11 (5): 339-352. 10.1006/scbi.2001.0389.CrossRefPubMed
8.
Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB: Exploiting the PI3K/AKT pathway for cancer drug discovery. Nature reviews. 2005, 4 (12): 988-1004. 10.1038/nrd1902.PubMed
9.
Rau KM, Kang HY, Cha TL, Miller SA, Hung MC: The mechanisms and managements of hormone-therapy resistance in breast and prostate cancers. Endocrine-related cancer. 2005, 12 (3): 511-532. 10.1677/erc.1.01026.CrossRefPubMed
10.
Glaeser M, Floetotto T, Hanstein B, Beckmann MW, Niederacher D: Gene amplification and expression of the steroid receptor coactivator SRC3 (AIB1) in sporadic breast and endometrial carcinomas. Horm Metab Res. 2001, 33 (3): 121-126. 10.1055/s-2001-14938.CrossRefPubMed
11.
Rochette-Egly C: Nuclear receptors: integration of multiple signalling pathways through phosphorylation. Cell Signal. 2003, 15 (4): 355-366. 10.1016/S0898-6568(02)00115-8.CrossRefPubMed
12.
Mills GB, Lu Y, Fang X, Wang H, Eder A, Mao M, Swaby R, Cheng KW, Stokoe D, Siminovitch K, Jaffe R, Gray J: The role of genetic abnormalities of PTEN and the phosphatidylinositol 3-kinase pathway in breast and ovarian tumorigenesis, prognosis, and therapy. Semin Oncol. 2001, 28 (5 Suppl 16): 125-141. 10.1016/S0093-7754(01)90290-8.CrossRefPubMed
13.
Isakoff SJ, Engelman JA, Irie HY, Luo J, Brachmann SM, Pearline RV, Cantley LC, Brugge JS: Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer research. 2005, 65 (23): 10992-11000. 10.1158/0008-5472.CAN-05-2612.CrossRefPubMed
14.
Li SY, Rong M, Grieu F, Iacopetta B: PIK3CA mutations in breast cancer are associated with poor outcome. Breast Cancer Res Treat. 2005, 1-5.
15.
Clark AS, West K, Streicher S, Dennis PA: Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol Cancer Ther. 2002, 1 (9): 707-717.PubMed
16.
Ali S, Coombes RC: Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer. 2002, 2 (2): 101-112. 10.1038/nrc721.CrossRefPubMed
17.
Felekkis KN, Narsimhan RP, Near R, Castro AF, Zheng Y, Quilliam LA, Lerner A: AND-34 activates phosphatidylinositol 3-kinase and induces anti-estrogen resistance in a SH2 and GDP exchange factor-like domain-dependent manner. Mol Cancer Res. 2005, 3 (1): 32-41.PubMed
18.
Guy CT, Webster MA, Schaller M, Parsons TJ, Cardiff RD, Muller WJ: Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proceedings of the National Academy of Sciences of the United States of America. 1992, 89 (22): 10578-10582. 10.1073/pnas.89.22.10578.CrossRefPubMedPubMedCentral
19.
Blanco-Aparicio C, Perez-Gallego L, Pequeno B, Leal JF, Renner O, Carnero A: Mice expressing myrAKT1 in the mammary gland develop carcinogen-induced ER-positive mammary tumors that mimic human breast cancer. Carcinogenesis. 2007, 28 (3): 584-594. 10.1093/carcin/bgl190.CrossRefPubMed
20.
Maroulakou IG, Oemler W, Naber SP, Tsichlis PN: Akt1 ablation inhibits, whereas Akt2 ablation accelerates, the development of mammary adenocarcinomas in mouse mammary tumor virus (MMTV)-ErbB2/neu and MMTV-polyoma middle T transgenic mice. Cancer research. 2007, 67 (1): 167-177. 10.1158/0008-5472.CAN-06-3782.CrossRefPubMed
21.
Vadlamudi RK, Kumar R: Functional and biological properties of the nuclear receptor coregulator PELP1/MNAR. Nuclear receptor signaling. 2007, 5: e004-PubMedPubMedCentral
22.
Gururaj AE, Rayala SK, Vadlamudi RK, Kumar R: Novel mechanisms of resistance to endocrine therapy: genomic and nongenomic considerations. Clin Cancer Res. 2006, 12 (3 Pt 2): 1001s-1007s. 10.1158/1078-0432.CCR-05-2110.CrossRefPubMed
23.
Greger JG, Fursov N, Cooch N, McLarney S, Freedman LP, Edwards DP, Cheskis BJ: Phosphorylation of MNAR promotes estrogen activation of phosphatidylinositol 3-kinase. Mol Cell Biol. 2007, 27 (5): 1904-1913. 10.1128/MCB.01732-06.CrossRefPubMed
24.
Wong CW, McNally C, Nickbarg E, Komm BS, Cheskis BJ: Estrogen receptor-interacting protein that modulates its nongenomic activity-crosstalk with Src/Erk phosphorylation cascade. Proceedings of the National Academy of Sciences of the United States of America. 2002, 99 (23): 14783-14788. 10.1073/pnas.192569699.CrossRefPubMedPubMedCentral
25.
Dong ZY, Liu Y, Lu S, Wang A, Lee K, Wang LH, Revelo M, Lu S: Vav3 oncogene is overexpressed and regulates cell growth and androgen receptor activity in human prostate cancer. Mol Endo. 2006, 20: 2315-2325. 10.1210/me.2006-0048.CrossRef
26.
Lyons LS, Burnstein KL: Vav3, a Rho GTPase Guanine Nucleotide Exchange Factor, Increases During Progression to Androgen Independence in Prostate Cancer Cells and Potentiates Androgen Receptor Transcriptional Activity. Mol Endocrinol. 2005, December 29,
27.
Lu S, Tsai SY, Tsai MJ: Melecular mechanisms of androgen-independent growth of human prostate cancer LNCaP-AI cells. Endocrinology. 1999, 140: 5054-5059. 10.1210/en.140.11.5054.PubMed
28.
Zhang J, Kalkum M, Yamamura S, Chait BT, Roeder RG: E protein silencing by the leukemogenic AML1-ETO fusion protein. Science. 2004, 305 (5688): 1286-1289. 10.1126/science.1097937.CrossRefPubMed
29.
Zhang J, Kalkum M, Chait BT, Roeder RG: The N-CoR-HDAC3 nuclear receptor corepressor complex inhibits the JNK pathway through the integral subunit GPS2. Mol Cell. 2002, 9 (3): 611-623. 10.1016/S1097-2765(02)00468-9.CrossRefPubMed
30.
Lopez-Lago M, Lee H, Cruz C, Movilla N, Bustelo XR: Tyrosine phosphorylation mediates both activation and downmodulation of the biological activity of Vav. Mol Cell Biol. 2000, 20 (5): 1678-1691. 10.1128/MCB.20.5.1678-1691.2000.CrossRefPubMedPubMedCentral
31.
Tremblay A, Tremblay GB, Labrie F, Giguere V: Ligand-independent recruitment of SRC-1 to estrogen receptor beta through phosphorylation of activation function AF-1. Mol Cell. 1999, 3 (4): 513-519. 10.1016/S1097-2765(00)80479-7.CrossRefPubMed
32.
Yeh S, Lin HK, Kang HY, Thin TH, Lin MF, Chang C: From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proceedings of the National Academy of Sciences of the United States of America. 1999, 96: 5458-5463. 10.1073/pnas.96.10.5458.CrossRefPubMedPubMedCentral
33.
Zeng L, Sachdev P, Yan L, Chan JL, Trenkle T, McClelland M, Welsh J, Wang LH: Vav3 mediates receptor protein tyrosine kinase signaling, regulates GTPase activity, modulates cell morphology, and induces cell transformation. Mol Cell Biol. 2000, 20 (24): 9212-9224. 10.1128/MCB.20.24.9212-9224.2000.CrossRefPubMedPubMedCentral
34.
Sachdev P, Zeng L, Wang LH: Distinct role of phosphatidylinositol 3-kinase and Rho family GTPases in Vav3-induced cell transformation, cell motility, and morphological changes. J Biol Chem. 2002, 277 (20): 17638-17648. 10.1074/jbc.M111575200.CrossRefPubMed
35.
Houlard M, Arudchandran R, Regnier-Ricard F, Germani A, Gisselbrecht S, Blank U, Rivera J, Varin-Blank N: Vav1 is a component of transcriptionally active complexes. J Exp Med. 2002, 195 (9): 1115-1127. 10.1084/jem.20011701.CrossRefPubMedPubMedCentral
36.
Movilla N, Bustelo XR: Biological and regulatory properties of Vav-3, a new member of the Vav family of oncoproteins. Mol Cell Biol. 1999, 19 (11): 7870-7885.CrossRefPubMedPubMedCentral
37.
Voegel JJ, Heine MJ, Tini M, Vivat V, Chambon P, Gronemeyer H: The coactivator TIF2 contains three nuclear receptor-binding motifs and mediates transactivation through CBP binding-dependent and -independent pathways. Embo J. 1998, 17 (2): 507-519. 10.1093/emboj/17.2.507.CrossRefPubMedPubMedCentral
38.
Leo C, Chen JD: The SRC family of nuclear receptor coactivators. Gene. 2000, 245 (1): 1-11. 10.1016/S0378-1119(00)00024-X.CrossRefPubMed
39.
Tamas P, Solti Z, Bauer P, Illes A, Sipeki S, Bauer A, Farago A, Downward J, Buday L: Mechanism of epidermal growth factor regulation of Vav2, a guanine nucleotide exchange factor for Rac. J Biol Chem. 2003, 278 (7): 5163-5171. 10.1074/jbc.M207555200.CrossRefPubMed
40.
Fan P, Wang J, Santen RJ, Yue W: Long-term treatment with tamoxifen facilitates translocation of estrogen receptor alpha out of the nucleus and enhances its interaction with EGFR in MCF-7 breast cancer cells. Cancer research. 2007, 67 (3): 1352-1360. 10.1158/0008-5472.CAN-06-1020.CrossRefPubMed
41.
Marquez DC, Chen HW, Curran EM, Welshons WV, Pietras RJ: Estrogen receptors in membrane lipid rafts and signal transduction in breast cancer. Molecular and cellular endocrinology. 2006, 246 (1–2): 91-100. 10.1016/j.mce.2005.11.020.CrossRefPubMed
Metadata
Title
Vav3 oncogene activates estrogen receptor and its overexpression may be involved in human breast cancer
Authors
Kiwon Lee
Yin Liu
Jun Qin Mo
Jinsong Zhang
Zhongyun Dong
Shan Lu
Publication date
01-12-2008
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2008
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-8-158

Other articles of this Issue 1/2008

BMC Cancer 1/2008 Go to the issue

Research article

Comorbidity, age, race and stage at diagnosis in colorectal cancer: a retrospective, parallel analysis of two health systems

Research article

XM02 is superior to placebo and equivalent to Neupogen™ in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy

Research article

Voluntary exercise inhibits intestinal tumorigenesis in Apc Min/+mice and azoxymethane/dextran sulfate sodium-treated mice

Research article

P53 expression is significantly correlated with high risk of malignancy and epithelioid differentiation in GISTs. An immunohistochemical study of 104 cases

Research article

ERCC22251A>C genetic polymorphism was highly correlated with early relapse in high-risk stage II and stage III colorectal cancer patients: A preliminary study

Research article

Quantification of SLIT-ROBO transcripts in hepatocellular carcinoma reveals two groups of genes with coordinate expression
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits